- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| Di | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 25.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 22.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 2 | ASX | ||
| 21.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 3 | ASX | ||
| 20.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 07.10. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 2 | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.10. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | 2 | ASX | ||
| 05.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 02.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 3 | ASX | ||
| 01.10. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 30.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 29.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 25.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 24.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 22.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 2 | ASX | ||
| 21.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 18.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| 16.09. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 14.09. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 5,400 | +0,19 % | Forget Rescheduling: Green Thumb's Cash Flow Is the Real Reason to Own It | ||
| ALNYLAM PHARMACEUTICALS | 148,45 | +0,54 % | Alnylam Pharmaceuticals Inc. Reports Advance In Q3 Bottom Line | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) revealed earnings for its third quarter that Increases, from the same period last yearThe company's bottom line came in at $2.167 billion... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 34,270 | -1,58 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,575 | +1,05 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ADASTRA | 0,142 | 0,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 8,680 | +0,23 % | Sellas falls as REGAL trial nears final analysis | ||
| ACADIA PHARMACEUTICALS | 18,440 | +0,30 % | Acadia Pharmaceuticals Inc.: European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -1- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameAGP8696W1045 SINOVAC... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc.: Numinus Wellness Founders to Resume Original Executive Roles | Vancouver, British Columbia--(Newsfile Corp. - October 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral... ► Artikel lesen | |
| SOLIGENIX | 0,359 | +0,76 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| OPUS GENETICS | 3,300 | +0,61 % | Opus Genetics appoints chief scientific officer, operations head | ||
| ANI PHARMACEUTICALS | 65,00 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension | PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,300 | 0,00 % | ZELIRA THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | ||
| SAVARA | 4,336 | +1,05 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.